BR0213970A - Amidas de ácido antranìlico e uso farmacêutico dessas amidas - Google Patents

Amidas de ácido antranìlico e uso farmacêutico dessas amidas

Info

Publication number
BR0213970A
BR0213970A BR0213970-7A BR0213970A BR0213970A BR 0213970 A BR0213970 A BR 0213970A BR 0213970 A BR0213970 A BR 0213970A BR 0213970 A BR0213970 A BR 0213970A
Authority
BR
Brazil
Prior art keywords
treatment
amides
lower alkyl
disease
pharmaceutical use
Prior art date
Application number
BR0213970-7A
Other languages
English (en)
Inventor
Guido Bold
Pascal Furet
Paul William Manley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0213970A publication Critical patent/BR0213970A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"AMIDAS DE áCIDO ANTRANìLICO E USO FARMACêUTICO DESSAS AMIDAS". A invenção refere-se a derivados de amida de ácido antranílico de fórmula I, onde R~ 1~, representa H ou alquila inferior, R~ 2~ representa H ou alquila inferior, R~ 3~ representa perfluoraquila inferior, e X é O ou S, ou um N-óxido ou um tautómero dos mesmos, a sais dessas amidas de ácido antranílico, seus Nóxidos e seus tautómeros; a processos para a preparação dos mesmos; a aplicação dos mesmos para o tratamento do corpo humano ou animal, ao uso dos mesmos - separados ou em combinação com um ou mais outros compostos farmaceuticamente ativos - para o tratamento especialmente de doença neoplástica, tais como doença de tumor, de retinopatia ou degeneração macular relacionada com a idade; a um método para o tratamento dessas doenças em animais, especialmente em humanos, e ao uso desse composto - separado ou em combinação com um ou mais outros compostos farmaceuticamente ativos - para a produção de uma preparação farmacêutica para o tratamento de doença neoplástica, de retinopatia ou de degeneração macular relacionada com a idade.
BR0213970-7A 2001-11-08 2002-11-07 Amidas de ácido antranìlico e uso farmacêutico dessas amidas BR0213970A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126902.6A GB0126902D0 (en) 2001-11-08 2001-11-08 Organic compounds
PCT/EP2002/012444 WO2003040102A1 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR0213970A true BR0213970A (pt) 2004-08-31

Family

ID=9925448

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213970-7A BR0213970A (pt) 2001-11-08 2002-11-07 Amidas de ácido antranìlico e uso farmacêutico dessas amidas

Country Status (28)

Country Link
US (2) US7091224B2 (pt)
EP (1) EP1446382B1 (pt)
JP (1) JP2005511602A (pt)
KR (1) KR100602977B1 (pt)
CN (1) CN1300113C (pt)
AT (1) ATE496889T1 (pt)
AU (1) AU2002351909B2 (pt)
BR (1) BR0213970A (pt)
CA (1) CA2463968C (pt)
CO (1) CO5580823A2 (pt)
DE (1) DE60239073D1 (pt)
ES (1) ES2360283T3 (pt)
GB (1) GB0126902D0 (pt)
HR (1) HRP20040411A2 (pt)
IL (1) IL161747A0 (pt)
MX (1) MXPA04004391A (pt)
NO (1) NO327231B1 (pt)
NZ (1) NZ532590A (pt)
PE (1) PE20030714A1 (pt)
PL (1) PL368416A1 (pt)
PT (1) PT1446382E (pt)
RU (1) RU2318811C2 (pt)
SA (1) SA02230412B1 (pt)
TW (1) TWI260222B (pt)
UA (1) UA77446C2 (pt)
WO (1) WO2003040102A1 (pt)
YU (1) YU36004A (pt)
ZA (1) ZA200402940B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7999132B2 (en) 2004-12-07 2011-08-16 Toyama Chemical Co., Ltd. Anthranilic acid derivative or salt thereof
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101323629B (zh) * 2007-02-16 2011-08-17 江苏正大天晴药业股份有限公司 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-甲基磷酸二乙酯
US8350026B2 (en) 2008-08-27 2013-01-08 Leo Pharma A/S VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
CN107954893A (zh) * 2017-11-28 2018-04-24 兰州纬寰生物科技有限公司 邻氨基苯甲酰胺衍生物及制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
TWI260222B (en) 2006-08-21
EP1446382A1 (en) 2004-08-18
US7482369B2 (en) 2009-01-27
RU2318811C2 (ru) 2008-03-10
US20060178409A1 (en) 2006-08-10
HRP20040411A2 (en) 2005-04-30
PE20030714A1 (es) 2003-10-13
CN1585750A (zh) 2005-02-23
ES2360283T3 (es) 2011-06-02
ATE496889T1 (de) 2011-02-15
AU2002351909B2 (en) 2007-04-26
DE60239073D1 (de) 2011-03-10
CO5580823A2 (es) 2005-11-30
NO20042187L (no) 2004-05-26
JP2005511602A (ja) 2005-04-28
MXPA04004391A (es) 2005-12-12
IL161747A0 (en) 2005-11-20
UA77446C2 (en) 2006-12-15
US7091224B2 (en) 2006-08-15
CA2463968C (en) 2011-02-22
PL368416A1 (en) 2005-03-21
US20050096356A1 (en) 2005-05-05
NZ532590A (en) 2005-12-23
NO327231B1 (no) 2009-05-18
PT1446382E (pt) 2011-05-03
RU2004117543A (ru) 2006-01-10
EP1446382B1 (en) 2011-01-26
KR100602977B1 (ko) 2006-07-20
WO2003040102A1 (en) 2003-05-15
KR20050044382A (ko) 2005-05-12
YU36004A (sh) 2006-08-17
ZA200402940B (en) 2005-02-10
SA02230412B1 (ar) 2007-07-31
GB0126902D0 (en) 2002-01-02
CN1300113C (zh) 2007-02-14
CA2463968A1 (en) 2003-05-15
TW200300087A (en) 2003-05-16

Similar Documents

Publication Publication Date Title
BR0213970A (pt) Amidas de ácido antranìlico e uso farmacêutico dessas amidas
BRPI0116967A2 (pt) derivado de pirazina ou um sal deste, composição farmacêutica, e, derivado de fluoropirazina ou um sal deste
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
MY141597A (en) 2,4-disubstituted thiazolyl derivatives
DE60028740D1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
NO20060113L (no) Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer
DE602007004093D1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
MY136322A (en) Anthranilic acid amides and pharmaceutical use thereof
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
BR0317292A (pt) Derivados de amida de ácido antranìlico e seu uso farmacêutico
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
ECSP045092A (es) Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf
WO2005035500A3 (en) Therapeutic agents useful for treating pain
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
TH58670B (th) อนุพันธ์ 2-อะมิโน-3-(แอลคิล)-พิริมิโดน
TH88080B (th) "แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน"
TH88080A (th) แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน
UY27534A1 (es) Amidas de ácido antranílico y uso farmacológico de las mismas.
TH66266A (th) สารประกอบทางเคมี

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A E 18A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.